Korea Added to Ongoing Trials in Thailand and Vietnam
Direct Comparison with MSD's Varivax

GC Green Cross announced on July 2 that it has received approval from the Ministry of Food and Drug Safety for the Phase 3 clinical trial protocol (IND) of its chickenpox vaccine, 'Varicellavax,' for a two-dose (2-dose) regimen.


Exterior view of GC Green Cross headquarters. GC Green Cross

Exterior view of GC Green Cross headquarters. GC Green Cross

View original image

This clinical trial is a multinational study that adds Korea to the ongoing global trials in Thailand and Vietnam. It will enroll 474 healthy children aged between 12 months and 12 years. The study aims to directly compare Varicellavax to 'Varivax,' the chickenpox vaccine from Merck (MSD) in the United States, in order to assess the immunogenicity and safety of Varicellavax.


The chickenpox vaccine market is shifting toward a two-dose regimen to reduce breakthrough infections that can occur after a single dose. Twenty-eight countries, including major nations such as the United States, Canada, and Japan, have adopted the two-dose schedule, and the World Health Organization (WHO) also recommends two doses for chickenpox prevention.


Varicellavax is a vaccine developed by GC Green Cross in 1993, based on the 'MAV/06' strain. The MAV/06 strain was listed in the WHO chickenpox vaccine guidelines in November last year. It has established the same level of reliability as the conventional Oka-based chickenpox vaccines.


GC Green Cross plans to obtain product approval for the two-dose regimen in Korea and key Southeast Asian countries by 2028, following the completion of multinational clinical trials.



Jaeu Lee, Head of Development at GC Green Cross, said, "The two-dose clinical trial for Varicellavax is a key step in strengthening our vaccine portfolio's competitiveness," and added, "We will further expand its global market utilization."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing